Dr. Stephen C. Yang is a professor of surgery and medical oncology at Johns Hopkins University School of Medicine and The Johns Hopkins Hospital. In October 2008 he was named the first recipient of The Arthur B. and Patricia B. Modell Professor in Thoracic Surgery. Dr. Yang is an extreme supporter of medical students, being the only surgeon (amongst 20 chosen from the School of Medicine) for the medical student advisory Colleges system, and is the faculty sponsor for the Surgery Interest Group and the Asian Pacific American Medical Student Association. Dr. Yang graduated from Duke University with a B.A. in Chemistry and received his M.D. degree from the Medical College of Virginia. He completed his general surgery residency at the University of Texas Health Science Center at Houston, and finished his cardiothoracic surgery fellowship at the Medical College of Virginia. He also completed a 3 year thoracic surgical oncology research fellowship at the University of Texas M. D. Anderson Cancer Center. He currently serves on the Postgraduate Affairs, Medical School Admissions, Educational Policy, and Curriculum Reform Committees in the Johns Hopkins School of Medicine. He served on numerous national and international committees for these organizations, and is the Taskforce Chair on the Looking to the Future Residency Scholarships for the Society of Thoracic Surgeons He is Editor of Practical Reviews in Chest Medicine and guest editor/ reviewer for numerous peer review journals. He is co-editor of the book Current Therapy in Thoracic and Cardiovascular Surgery, edited the esophageal surgical section in the 2nd edition of Atlas of Gastrointestinal Surgery with John Cameron, M.D., and series editor-in-chief of The Early Diagnosis of Cancer also editing the book volume of The Early Diagnosis of Lung Cancer. In 2001, he and his lung transplant team were featured in the ABC series 24/7 and is currently also being followed in the sequel to that series focusing in on resident and medical student teaching. This series as well as other experiences are still shown on the Discovery Channel. The extensive work in preparing an esophageal cancer patient for surgery on the BBC and the Discovery Channel. Dr. Yang's laboratory research interests include using molecular techniques for lung cancer screening and for molecular staging of micrometastasis to predict recurrence following surgical resection. His clinical practice and research covers the breath of general thoracic surgery in pulmonary and esophageal surgery, video-assisted and robotics thoracic surgery, mediastinal and pleural work, lung volume reduction surgery for emphysema, and work in geriatric thoracic surgery. Dr. Yang is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, Endoscopy, and Thymectomy.

Richard Battafarano, M.D., Ph.D., joins the Johns Hopkins Department of Surgery as director of the Division of General Thoracic Surgery and the first regional director of general thoracic surgery. He comes to Johns Hopkins from University of Maryland Medical System, where he was chief of the Division of Thoracic Surgery. Dr. Battafarano specializes in the treatment of benign and malignant diseases and lesions of the chest, including minimally invasive operations such as video-assisted thoracscopic surgery (VATS) for lung and esophageal cancers. He also has a special interest in treating Barretts esophagus, emphysema, mesothelioma and paraesophageal hernias. The focus of Dr. Battafaranos basic and translational research includes outcomes in the surgical management of early stage lung cancer patients with neuroendocrine histology, optimal management of lung cancer patients with mediastinal lymph node metastases, and the effect of survivin overexpression in the development of esophageal cancer. Dr. Battafarano sees patients at The Johns Hopkins Hospital and the Johns Hopkins Health Care & Surgery Centers at Green Spring Station and at White Marsh. Dr. Battafarano is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Thymic Epithelial Tumor, Pleuropulmonary Blastoma, Gastrectomy, and Endoscopy.

Sylwester Dziuba is a Radiation Oncologist in Owings Mills, Maryland. Dr. Dziuba is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Lung Cancer, and Pleuropulmonary Blastoma. Dr. Dziuba is currently accepting new patients.

Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.

Patrick Forde is a Hematologist Oncology specialist and an Oncologist in Baltimore, Maryland. Dr. Forde is rated as an Elite provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, Small Cell Lung Cancer (SCLC), and Bone Marrow Transplant. Dr. Forde is currently accepting new patients.

Malcolm V. Brock, M.D., a graduate of the Johns Hopkins University School of Medicine, the Johns Hopkins general surgical residency program and the Johns Hopkins fellowship in cardiothoracic surgery, is a specialist in thoracic oncology, and is a Professor of Surgery and Oncology at the Johns Hopkins University School of Medicine. In additional to clinical thoracic oncology, his clinical interests include surgery for palmar, axillary and pedal hyperhidrosis. Dr. Brock is a surgeon who conducts cancer research at the Johns Hopkins Kimmel Cancer Center, specializing in applying innovative basic science research to patient care. His main research interests are in developing novel molecular biomarkers for solid tumors that can help clinicians diagnose cancer earlier and treat it more effectively. He has studied using DNA-based methods to predict which patients will develop recurrent lung cancer, even after successful surgery, and to predict patients with esophageal cancer who will be sensitive to certain chemotherapy. Dr. Brock has published over 70 original research papers, book chapters and review articles, and has presented often at national and international conferences. He has been the recipient of research funding from the National Institutes of Health (NIH), the Thoracic Surgery Foundation for Research Excellence, the American College of Surgery Oncology Group and the Society of Surgical Oncology. Dr. Brock is rated as an Advanced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Lung Cancer, Esophageal Cancer, Non-Small Cell Lung Cancer (NSCLC), Tissue Biopsy, and Endoscopy.

Syed Nasir is a Hematologist and an Oncologist in Towson, Maryland. Dr. Nasir is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Familial Colorectal Cancer, Colorectal Cancer, Lynch Syndrome, and Paget Disease of the Breast.

William Houck is an Oncologist in Baltimore, Maryland. Dr. Houck is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Paget Disease of the Breast, Lung Cancer, Chronic B-Cell Leukemia (CBCL), and Chronic Lymphocytic Leukemia (CLL).

Dr. Kristin Redmond specializes in the treatment of brain tumors and leads the spinal radiosurgery program. She received her undergraduate degree from Princeton University where she graduated magna cum laude with a focus in neuro-psychology. She attended medical school and obtained a Masters in Public Health in health systems management at Tulane University where she was elected to the Alpha Omega Alpha Honor Medical Society as well as the Gold Humanism in Medicine Honor Society. Dr. Redmonds research interest focuses on the development of novel radiation techniques and therapeutic agents to treat brain and spine tumors in order to increase tumor control and overall survival. In addition, she is working to develop innovative approaches to try to limit long term toxicities and minimize neuro-cognitive dysfunction following treatment for tumors of the central nervous system. Dr. Redmond believes in a holistic approach to medicine and feels that the social and psychological components of patient care are equally important to traditional therapies. She works closely with a team of specialists to support patients and families during their cancer journey. Make A Gift. Dr. Redmond is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Chordoma, Brain Tumor, Astrocytoma, and Metastatic Brain Tumor.

Dr. Yarmus is a Professor of Medicine and Oncology and the director of Interventional Pulmonology at the Johns Hopkins University School of Medicine as well as the Vice Chair of Medicine for Strategy and Finance. He is an expert in the minimally invasive diagnosis and treatment of lung cancer and he leads the Interventional Pulmonary research program at Johns Hopkins with research investigating innovative minimally invasive device development and early-stage bronchoscopic treatments. He also has extensive experience in the minimally invasive management of malignant airway obstruction, complex airway management, pleural diseases and symptom relief with minimally invasive procedures such as indwelling pleural catheters and pleurodesis. Dr. Yarmus is a member of the Fleischner Society and a fellow of the American College of Chest Physicians and the American Thoracic Society. Dr. Yarmus is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Pleural Effusion, Lung Nodules, Lymphofollicular Hyperplasia, Endoscopy, and Advanced Bronchoscopy.

Dr. Anagnostou is an Associate Professor of Oncology, co-director of the Upper Aerodigestive Malignancies Program, director of the Thoracic Oncology Biorepository, leader of Precision Oncology Analytics and co-leader of the Molecular Tumor Board and the Thoracic Oncology Precision Medicine Center of Excellence in the Sidney Kimmel Cancer Center at Johns Hopkins. She has established the Molecular Oncology laboratory that seeks to understand the genomic wiring of response and resistance to immunotherapy through integrative genomic, transcriptomic, single-cell and liquid biopsy analyses of tumor and immune evolution. Dr. Anagnostou graduated from Medical School of the National and Kapodistrian University of Athens, Greece and received a PhD from the same institution. After completing her internal medicine residency at Yale-New Haven Hospital, she subsequently trained in Medical Oncology at Johns Hopkins. Dr. Anagnostou is a translational cancer investigator, focusing on large-scale genomic and liquid biopsy analyses in human cancers. Her group has discovered novel genomic mechanisms of response and resistance to immunotherapy and her research is particularly focused on understanding the molecular mechanisms of response and resistance to these therapies, capturing these by minimally invasive methods and translating this knowledge into novel technologies and innovative therapeutic approaches for cancer patients. She is the international study chair of the first ctDNA-based molecular response adaptive immuno-chemotherapy clinical trial for metastatic non-small cell lung cancer (NCT04093167). Dr. Anagnostou's long term goal is to transform medical oncology to personalized molecular oncology, where treatment decisions are tailored to cancer genomics and molecular real-time response assessments informed by liquid biopsies. Dr. Anagnostou is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Mesothelioma, and Gastroesophageal Junction Cancer.

Dr. Lee is a specialist in Interventional Pulmonary and serves as the Wang Interventional Pulmonary Fellowship Director. His areas of clinical expertise include interventional pulmonology, pleural disease, minimal invasive diagnostics and lung cancer at Johns Hopkins. He also has extensive experience in the minimally invasive management of malignant airway obstruction, complex airway management and difficulty airways. In addition, he specializes in the diagnosis and management of pleural diseases and symptom relief with minimally invasive procedures. He is a fellow of the American College of Chest Physicians and the Johns Hopkins Master of Education for Health Professionals. Dr. Lee is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Pleural Effusion, Lung Nodules, Lymphofollicular Hyperplasia, Endoscopy, and Advanced Bronchoscopy.

Troy Brijbasi is a Radiologist and an Interventional Radiologist in Owings Mills, Maryland. Dr. Brijbasi is rated as an Advanced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Ascites, Pleurisy, Lung Nodules, Bone Marrow Aspiration, and Gastrostomy.

Amit Kalaria is an Interventional Radiologist and a Radiologist in Owings Mills, Maryland. Dr. Kalaria is rated as an Advanced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Ascites, Lung Nodules, Lung Cancer, Bone Marrow Aspiration, and Liver Embolization.

Mark Katlic is a Thoracic Surgeon in Randallstown, Maryland. Dr. Katlic is rated as an Advanced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Endoscopy, and Thymectomy.

David Ettinger is an Oncologist in Lutherville, Maryland. Dr. Ettinger is rated as a Distinguished provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), and Thymic Epithelial Tumor.

Dr. William H. Sharfman is an associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include cutaneous oncology, dermatology and immunotherapy. He helped create the well-established Melanoma Program at the Johns Hopkins Kimmel Cancer Center in 1994. Dr. Sharfman serves as the director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program. He earned his M.D. from the University of Toledo College of Medicine. He completed his residency at Cleveland Clinic and performed a fellowship in hematology and oncology at Cleveland Clinic. Dr. Sharfman's research interests include novel therapies for high risk and advanced melanoma patients. Dr. Sharfman is rated as an Experienced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Eccrine Porocarcinoma, and Familial Pancreatic Cancer.

Dr. Sydney Morss Dy currently practices with the Primary Care for Cancer Survivors Program at Green Spring Station. She holds a joint appointment in medicine and in oncology at the Johns Hopkins University School of Medicine. She is a professor of health policy and management at the Johns Hopkins University Bloomberg School of Public Health. Her areas of clinical expertise include cancer survivorship, internal medicine, and palliative care. For many years, she was the physician for the pain and symptom management clinic in the Cancer Center and for Hopkins' cancer case management program. Dr. Dy earned her M.D. and her M.Sc. in health services research from the Stanford University School of Medicine. She completed both a residency and a fellowship at Johns Hopkins before joining the faculty in 2001. Dr. Dy is rated as an Experienced provider by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Lung Cancer, Angiosarcoma, Opioid Induced Constipation, and Throat Cancer.

Dr. Howard Steiner is an instructor of medicine at the Johns Hopkins School of Medicine. He has been practicing pulmonary and sleep consultative medicine since 1989. In his role as a diagnostician, he guides the evaluation and management of respiratory problems including infectious, malignant, allergic, autoimmune, and sleep-related disorders. He has been part-time faculty in the Johns Hopkins Pulmonary Division since 1991, is a Fellow in the American College of Chest Physicians, and mentors medical students, residents, and pulmonary fellows training at the Johns Hopkins Hospital. Contact for Research Inquiries 10755 Falls Road Pavilion I, Suite 200 Lutherville, MD 21093 Phone: (410) 583-7124 Selected Publications Lwebuga-Mukasa JS, Steiner H. Monoclonal antibody to rat lung Maclura Pomifera agglutinin (MPA) lectin binding glycoprotein localizes apically on rat and human type II pneumocytes and Clara cells. J Cell Biol 107:71a, 1989. Roberts PJ, McBean GJ, Steiner H, Kohler C, Schwarcz R. Lesioning Effects of Ibotenate in the immature rat brain and protection by 2-amino-7 phosphonoheptanoic acid. Soc Neurosci Abst 9:261, 1983. Steiner H, Ingbar DI. Mechanisms of lung injury and repair. In: Matthay RA, Matthay MA, Wiedemann HP eds. Annual Review of Pulmonary and Critical Care Medicine. Hanley & Belfus (Philadelphia, 1989), pp 205-223. Steiner H, Lwebuga-Mukasa JS. A549 cells display distinct functional and morphologic properties depending on their culture substratum. J Cell Biol 107:71a, 1989. Steiner H, Lwebuga-Mukasa JS. A549 cells produce a factor which is Mitogenic for human lung fibroblasts. Amer Rev Resp Dis 139:A492 1989. Steiner H, McBean GJ, Kohler C, Roberts PJ, Schwarcz R. Ibotenate Induced neuronal degeneration in immature rat brain. Brain Research 307:117-124, 1984. Dr. Steiner is rated as an Experienced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Bronchiectasis, Obstructive Sleep Apnea, Lung Metastases, and Interstitial Lung Disease.

Otis Brawley is professor of oncology at the Johns Hopkins University School of Medicine and 39th Bloomberg Distinguished Professor at Johns Hopkins. Dr. Brawley leads a broad interdisciplinary research effort of cancer health disparities at the Johns Hopkins Bloomberg School of Public Health and the Johns Hopkins Kimmel Cancer Center, working to close racial, economic and social disparities in the prevention, detection and treatment of cancer in the United States and worldwide. He also directs community outreach programs for underserved populations throughout Maryland as the Kimmel Cancer Center’s associate director for community outreach and engagement. A former professor of oncology and hematology and deputy director for cancer control at the Winship Cancer Institute at Emory University in Atlanta, Dr. Brawley is a member of the National Academy of Medicine and recently received the Martin D. Abeloff Award for Excellence in Public Health and Cancer Control from the Maryland State Council of Cancer Control. The award, named after the director of the Kimmel Cancer Center from 1992 until his death in 2007, was established to recognize advancements made in cancer control practices that influenced the field of public health on a statewide, national or global scale. A graduate of the University of Chicago’s Pritzker School of Medicine, he completed an internal medicine residency at University Hospitals of Cleveland, Case-Western Reserve University and a fellowship in medical oncology at the National Cancer Institute. Dr. Brawley is rated as an Experienced provider by MediFind in the treatment of Lung Cancer. His top areas of expertise are Prostate Cancer, Triple-Negative Breast Cancer, Breast Cancer, Prostatectomy, and Colonoscopy.